Accelerated Aging Versus Real-Time Stability Data for Device Shelf-Life Claims

Accelerated aging versus real-time stability data in FDA device submissions: how shelf-life and storage claims are supported

For medical devices reviewed through the 510(k) and De Novo pathways, a labeled shelf life is not a marketing figure. It is a design output that FDA expects a manufacturer to justify with data showing the device still performs as labeled, and any sterile barrier still maintains sterility, at the end of the claimed storage period. Accelerated aging and real-time aging are the two evidentiary routes to that justification, and reviewers treat them as complementary rather than interchangeable: accelerated data buys speed, while real-time data provides definitive confirmation. This article summarizes how FDA weighs the two, drawn from device-specific FDA guidance and from the aging strategies actually accepted in recent De Novo and 510(k) decisions.

Shelf life is a design and reliability activity, not a single test

FDA frames shelf life as a product-reliability question that begins in preproduction planning. The manufacturer sets a target shelf life that accommodates shipping, storage, and use, then defines specifications and tolerances for the characteristics needed to assure labeled performance across that period, evaluating the device's materials, components, manufacturing and sterilization processes, packaging, intended use, and the risks of degradation or failure over time ³²²⁸. Because a shelf-life claim rests on written procedures for sampling, sample storage, aging parameters, shipping simulation, and follow-up action, reviewers look for a documented program rather than an isolated study, with results used to set storage limits, refine packaging, and apply expiration dating ⁴⁵.

A complete shelf-life claim generally has two distinct components that FDA evaluates on separate evidence:

Sterile barrier / package integrity — whether the packaging continues to maintain sterility over the labeled period. Sterility maintenance is determined primarily by continued package and seal integrity, not by re-sterilization ³⁶.
Device functional performance — whether the physical, mechanical, and functional properties of the aged device remain within specification. Shelf-life studies should repeat the bench tests that assess components or characteristics potentially affected by aging, using aged devices, and provide a rationale where a relevant test is not repeated ³⁴⁴¹.

Terminal sterility itself is usually addressed separately, through validation of the sterilization process (commonly ethylene oxide or radiation) to a sterility assurance level of 10^-6, while aged-package testing addresses whether that sterile barrier survives the shelf life ¹²¹².

How FDA weighs accelerated aging

Accelerated aging is accepted to support an initial or tentative shelf-life claim, letting a manufacturer place a product on the market before real-time data has fully matured. The central FDA-recognized standard is ASTM F1980, Standard Guide for Accelerated Aging of Sterile Barrier Systems for Medical Devices, which reviewers repeatedly cite as the expected basis for the aging model ³⁰³⁴. FDA's conditions for accepting accelerated data are specific:

Document how the packaged device was aged and identify the exact environmental parameters (temperature, and where relevant humidity) used to derive the expiration date ³⁰³⁴.
Provide a scientific rationale that the accelerated-aging results represent real-time aging ³⁰³⁴. This is the crux of the review: an Arrhenius-type acceleration model is only as good as the assumption that the degradation mechanism at elevated temperature matches the mechanism at normal storage temperature.
Justify the accelerated conditions particularly where degradation mechanisms may differ at elevated versus ambient temperatures, which is where accelerated models most often fail ⁵⁰.

Because of that last point, FDA is more cautious about accelerated-only data for polymeric materials, coatings, and components whose aging chemistry is temperature-sensitive, and recommends confirming accelerated results with real-time-aged samples in those cases ²⁹³⁰⁴¹.

How FDA weighs real-time aging

Real-time aging is treated as the definitive method for determining the actual effect of aging on sterility and device performance ²⁹³⁰⁴¹. Its practical advantage in a premarket submission is a timing accommodation: FDA guidance commonly permits a real-time study to run in parallel with review, with the protocol and interim results maintained in the design history file and the study completed on its natural timeline ²⁹³⁰⁴¹. Several device-specific guidances make the confirmatory expectation explicit. For implantable minimally invasive glaucoma surgical (MIGS) devices, FDA states that accelerated studies may establish an initial shelf life but a confirmatory real-time study should be performed ³¹; for implanted brain-computer interface devices, FDA recommends a concurrent real-time-aging protocol as part of the accelerated-aging shelf-life protocol ⁴⁴.

The package-validation study FDA expects to see

For sterile devices, submissions should describe the sterile-barrier packaging, explain how it maintains sterility, and identify the package-integrity test methods, with the depth of data scaled to the device type ⁹³. FDA points to the recognized ISO 11607-1 and ISO 11607-2 series for sterile barrier systems and for validation of forming, sealing, and assembly processes ²⁹³⁴. A package-validation study generally includes:

Simulated distribution / shipping, followed by package-integrity testing. For sterile devices, simulated shipping and climatic conditioning should precede package testing where applicable ⁴⁷.
Aging (accelerated and/or real-time), followed by seal-strength testing ²⁹³⁴⁹³.
Seal and material integrity tests addressing both the packaging material and the seals: visual seal inspection, bubble/gross-leak, burst, dye-penetration, and seal-strength testing ⁴⁷¹⁰¹.

The device-specific guidances illustrate how granular this can get. For peripheral PTA and specialty catheters, FDA recommends seal-strength assessment at baseline and after aging, with accelerated aging accompanied by real-time confirmatory testing, to show seals will not be compromised by applied forces ⁴⁷¹⁰¹. For breast implants, FDA recommends testing whole-package and seal integrity at time zero, then repeating functional integrity testing after manufacturing, sterilization, distribution, handling, vibration, and storage, and at intervals throughout shelf life ⁹². For IVDs, storage instructions should identify the applicable conditions (temperature, light, humidity) and stability/expiration dating should be established for the proposed container-closure system while accounting for package and shipping-container performance ³⁵⁵¹.

What the De Novo record shows

Across recent De Novo grants, accelerated aging under ASTM F1980 was routinely accepted as the principal support for an initial labeled shelf life, provided it was paired with post-aging package-integrity and functional testing.

The Acclarent Aera Eustachian Tube Balloon Dilation System (DEN150056) claimed a 2-year shelf life based on ASTM F1980-07 accelerated aging, with post-aging visual seal inspection (ASTM F1886), gross-leak testing (ASTM F2096-11), and seal-strength testing (ASTM F88-09), plus functional testing after EO sterilization, conditioning, shipping simulation, and aging; a real-time 2-year study had been initiated to confirm the claim ¹².
The esolution Esophageal Retractor (DEN230006) established a 1-year shelf life on ASTM F1980-16 accelerated aging with label inspection, bubble-leak (ASTM F2096), seal strength (ASTM F88), and functional testing of aged samples ³.
The Revi System implant (DEN220073) used ASTM F1980-16 for a 1-year shelf life, with ASTM D4169 shipping simulation preceding package-integrity testing, EO sterilization to SAL 10^-6 under ISO 11135, and EO/ECH residual testing under ISO 10993-7 ⁶.
The Sentinel Cerebral Protection System (DEN160043) supported a 1-year shelf life with accelerated aging equivalent to 13 months under ASTM F1980-07, followed by visual inspection (ASTM F1886), bubble-leak (ASTM F2096), seal-strength (ASTM F88), and repeat engineering bench testing ¹².

Other De Novo devices used accelerated aging in the same role, including ProdiGI (DEN220006, 1.5-year claim) ¹⁴, LOADPRO (DEN180012, 6- and 12-month claims) ⁸, the PREVENA 125 / PREVENA PLUS 125 Therapy Units (DEN180013, 3-year-equivalent aging of canisters and tubing) ²⁵, the Retrograde Intubation Set (DEN170055, 5-year aging) ⁷, and the non-sterile ONE Male Condom (DEN210034, two accelerated protocols supporting a 5-year claim) ¹⁷.

A second group of grants paired accelerated with real-time aging, treating the two as joint evidence rather than relying on acceleration alone. XSTAT (DEN130016) tested applicator deployment force and sponge-expansion rate under both 6-month real-time and 50°C/25-day accelerated conditions ⁵; the BIO-SEAL Lung Biopsy Tract System (DEN090007; K082438) supported a 3-year shelf life with accelerated aging (55°C, >70% RH, ASTM F1980) plus real-time ambient aging, testing samples at 1, 1.5, 2, 2.5, and 3 years ¹⁰; SafeBreak Vascular (DEN190043) combined non-aged, 1-year accelerated, and 1-year real-time devices ¹³; and IlluminOss (DEN160062) ²², BioXmark (DEN220017, 2-year dual aging) ²³, and the non-sterile N-SWEAT Patch (DEN210055) ²¹ followed similar dual-track designs.

A third group leaned on real-time aging for direct performance evidence where storage effects were harder to predict from an acceleration model. The InSpace Subacromial Tissue Spacer System (DEN200039) determined shelf life from real-time-aged samples out to 3 years, comparing 1-year real-time, 3-year accelerated, and 3-year real-time devices ⁴; the Hemolung Respiratory Assist System (DEN210006) used 2-year real-time-aged product to evaluate gas exchange, pump characterization, reliability, and heparin stability, reserving accelerated data for attributes not expected to change with age ¹⁹; and Trevo Retrievers (DEN150049) supported a 24-month claim using accelerated testing for some configurations and real-time testing for others, with broad component functional testing in both ⁹. The Kerasave grant (DEN200063) is notable for storage-condition-specific claims (24 months for corneal storage media at 2 to 8°C, plus a separate claim for Amphotericin B tablets at 4°C) supported by both real-time and accelerated studies together with short-term high-temperature challenge ²⁰.

What the 510(k) record shows

The 510(k) pattern mirrors the De Novo record. Accelerated aging under ASTM F1980 was the predominant route to an initial labeled shelf life for sterile, packaged devices, followed by package/sterile-barrier and functional testing. Recent examples include a 5-year claim for the Female/Male Culture, Transfer and Access Devices (K252899) verified by ASTM F1980-16 aging with ASTM D4169 shipping, ASTM F88 seal strength, ASTM F1929 dye penetration, ASTM F1140 internal-pressure testing, and USP <71> sterility ⁵⁶; a 3-year claim for RayFlow (K222023) with sealing validated under ISO 11607-1/-2 ⁷⁹; 5-year claims for an Insulin Syringe (K230061) ⁷⁶ and a Sterile Syringe Bulk Tray (K230447) ⁷⁸; and a 3-year claim for the Leksell Vantage Stereotactic System (K171123), whose ASTM F1980-07 program combined ASTM F1886, F1929, and F88 package tests with ASTM D4169 transport and ISO 11737-2 to demonstrate sterility after transport and storage ⁶⁸.

Real-time aging appeared in 510(k)s both as the primary demonstration and as explicit confirmation of accelerated results. The Neuralytix iD3 System (K243636) maintained sterile packages for 3 years of real-time aging before ASTM F88 seal-strength and ASTM F2096 bubble-leak testing, while separately using 1-year ASTM F1980-21 accelerated aging for its non-sterile adhesive patches ⁶². The clearest dual example is BD Vacutainer Plasma Separator and Sodium Heparin tubes (K252040), which aged product at 40°C/50% RH for 13 to 18 months under an Arrhenius approach and completed real-time aging at 25°C/50% RH over the same interval specifically to confirm the accelerated results, backed by draw-volume, leakage, centrifugation, gel-barrier, and shipping tests ⁸⁰. A self-seal sterilization pouch submission (K183356) validated a 2-year claim by a real-time aging method ⁶³, and nitrile chemotherapy examination gloves (K254285) supported a 5-year expiration claim with real-time testing (including ASTM D6978 permeation on gloves aged through 5 years) alongside accelerated tensile criteria ⁶⁴. For non-package IVD and reagent products, the typical pattern was real-time storage to establish actual stability supported by higher-temperature accelerated studies, as seen in CYBOW 11 Reagent Strips (K052525, 24-month claim from real-time plus 40/50/60°C studies) ⁷⁰ and SPOTCHEM II Chemistry Basic Tests (K053401) ⁷⁷.

Practical takeaways for submission strategy

Read together, the guidance and the cleared and granted submissions point to a consistent reviewer posture:

Accelerated aging can carry an initial shelf-life claim, but only when the acceleration model is documented, the environmental parameters are specified, and a scientific rationale ties the accelerated result to real-time behavior ³⁰³⁴.
Real-time aging is the confirmatory standard, and FDA will often let it run in parallel with review and reside in the design history file, so a manufacturer can launch on accelerated data while the real-time study matures ²⁹³⁰⁴¹.
The two claim components are proven separately: sterile-barrier integrity through package and seal testing (ISO 11607 framework, ASTM F88/F1929/F2096/F1140 and related methods) after simulated distribution and aging, and device functionality through repeat bench testing on aged units ²⁹³⁴⁹³⁴⁷¹⁰¹.
Material-, deployment-, or system-dependent risk raises the bar for real-time confirmation, which is why polymeric, coated, implantable, and functionally complex devices in the record more often paired the two approaches or led with real-time data ²⁹³⁰⁴¹⁵⁰.
Storage-condition claims must be matched to the tested conditions, including refrigerated ranges and defined temperature/humidity limits, rather than assumed from an ambient study ³⁵⁵¹²⁰.

For a given device type, the fastest way to calibrate FDA's specific expectations is to read the device-specific guidance where one exists and to review the aging design accepted in the closest cleared predicate or granted De Novo, since the standards, aging durations, and post-aging test batteries FDA has already accepted are the most direct evidence of what a reviewer will expect.